For CHC patients without hyper-resistinemic genotypes for the 4 RETN SNPs, in addition to the IFNL3 “CC” genotype, pre-therapy resistin levels >3.956 ng/ml may serve as a feasible criterion for predicting favorable interferon-based therapeutic responses. The gene discussed is IFNL3; the disease is cryohydrocytosis.